NCT04425291View on ClinicalTrials.gov

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

PHASE3CompletedINTERVENTIONAL
Enrollment

1,680

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

September 6, 2021

Study Completion Date

September 6, 2021

Conditions
Cervical CancerVulvar CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AIS
Interventions
BIOLOGICAL

4-valent HPV Vaccine

Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.

BIOLOGICAL

9-valent HPV Vaccine

Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

BIOLOGICAL

GARDASIL®

Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.

Trial Locations (1)

Unknown

Yangchun Center For Disease Prevention And Control, Yangchun

All Listed Sponsors
collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT04425291 - Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | Biotech Hunter | Biotech Hunter